As of the last check today, BWX Technologies, Inc. (NYSE: BWXT) share were rising 7.31% to $115.49, continuing an upward trajectory that was initiated by the recent completion of a significant acquisition. On May 20, 2025, the business formally closed the acquisition of Kinectrics, Inc., signifying enhanced capabilities across several nuclear industry areas and a major expansion of its commercial activities.
Complementary Nuclear Innovation Strengths
The transaction, which was first revealed in January, combines BWXT and Kinectrics’ complementary qualities. This calculated action is expected to increase BWXT’s presence in the nuclear medical and commercial nuclear power sectors.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Based in Toronto, Canada, Kinectrics offers a full range of lifecycle management services designed specifically for nuclear power facilities, especially those that use CANDU technology. Additionally, it is essential to the radiopharmaceutical industry’s isotope synthesis, transmission, and distribution.
Leadership Continuity and Operational Growth
With its finances integrated into BWXT’s Commercial Operations section, Kinectrics will operate as a fully owned subsidiary under the BWXT umbrella after the merger. The size of BWXT’s commercial team is almost doubled by the combined staff, allowing for a wider range of services for both current and potential customers. Kinectrics’ President and CEO, David Harris, will remain in charge of the division and answer to the senior leadership of BWXT.
A Common Goal for Advancement in Nuclear and Medicine
BWXT is now able to provide more comprehensive, end-to-end solutions for the nuclear lifecycle thanks to this purchase. It is anticipated that utilities would benefit from the synergy between the two companies as they develop nuclear energy through new construction and life extension programs.
The partnership also strengthens assistance for small modular reactor developers and improves the medical isotope supply’s dependability, both of which are critical for the advancement of cancer therapies.
Kinectrics strengthens BWXT’s position as a leader in the changing global nuclear environment by adding size and depth to its operational approach. Kinectrics’ commercial power and nuclear medical operations are expected to generate around US$300 million in 2024.
